Loading page…

Report overview

The report presents 2022 Group revenue of €196.3 million alongside continued oncology and RNAi development. Its non-financial disclosures cover workforce diversity, supply chain, environment, waste reuse, and ethics. The Group reports a 42% Scope 1 and 2 reduction target for 2030 and a net-zero target for 2050, and states that the Board oversees sustainability and non-financial information.

Document

Report type: Annual Report with Sustainability Disclosures
Class: Embedded
Scope: Full report
Fiscal year: 2022
Period: 1 January 2022 – 31 December 2022
Language
Pages
File size
Restatement: Disclosed

Standards & Assurance

Standards

GRI
SASB
TCFD
ISSB
ESRS
Integrated Reporting Framework
GHG Protocol
EU Taxonomy
CDP
Other

Commitments

UN Global Compact
UN Guiding Principles
Science Based Targets initiative

Ratings

SBTi status

Assurance

Statement included

ESG & Materiality

ESG data

Indicators available in this report:

Employees
Women on the board
Net zero target

Materiality

Assessment
Basis

Build your research dataset.

Original reports, structured indicators and machine-readable Markdown, tailored to your project.

Explore our services